Kurkuminin insan servikal kanseri Hep2C hücre hattı üzerindeki antiproliferatif ve sitotoksik etkileri

Amaç: Bu çalışmada, kurkuminin servikal kanser hücresi Hep2C üzerindeki antiproliferatif ve sitotoksik etkisi mikroskobik yöntemlerle ve MTT testi aracılığı ile araştırılmıştır. Yöntem: Hücre kültüründe çoğaltılan Hep2C (insan karsinoma kanser hücre hattı, ATCC:CCL-23) hücreleri, farklı kurkumin konsantrasyonlarına; 30 μg/ml, 15 μg/ml, 7,5 μg/ml, 3,7 μg/ml, 1,9 μg/ml, 0,9 μg/ml, 0,45 μg/ml, 24 saat boyunca maruz bırakılmıştır. Bu hücreler MTT protokolü uygulanarak test edilmiştir. 24 saatlik maruz bırakılmadan sonra Spectramax I3 cihazıyla absorbans değerlerine dayalı grafik ve IC50 değeri elde edilmiştir. MTT (3-[4,5-dimetiltiyazol-2-il]- 2,5-difenil-tetrazolyum bromür) testine dayalı olarak Hep2C hücrelerinin canlılık oranları tespit edilmiştir. Bu hücrelerdeki çekirdek ve yapısal değişiklikler inverted mikroskopla gözlemlenmiştir (Leica Microsystems). İşlem görmemiş hücreler negatif kontrol olarak kullanılmış ve pozitif kontrol için Hep2C hücreleri, yukarıda verilen inkübasyon süresi boyunca amonyum molibdata (1 mg/ ml) maruz bırakılmıştır. Bulgular: Yüksek dozlarda kurkumin (30 μg/ml, 15 μg/ml, 7,5 μg/ml) Hep2C hücrelerinde yüksek oranda antiproliferatif ve sitotoksik etki göstermiştir. Daha düşük konsantrasyonda kurkumin uygulanan Hep2C servikal kanser hücre hattında antiproliferatif ve sitotoksik etki gözlenmemiştir. Sonuç: Kurkuminin toksik olmadığı, yüksek oranda antioksidan ve antienflamatuvar ajan olarak kullanılabileceği ve çok yönlü terapötik- farmakolojik etkilere sahip olduğu gösterilmiştir. Ancak kurkuminin servikal kanser dokusundaki antiproliferatif, anti kanser etkileri konusundaki araştırmalar yeterli düzeyde değildir. Bu çalışmada kurkuminin ilk kez, servikal kanser hücresi Hep2C üzerindeki antiproliferatif ve sitotoksik etkisi mikroskobik yöntemlerle ve MTT testi aracılığı ile araştırılmıştır. Çalışmamızın sonuçları ile Hep2C hücrelerinde antiprolatif ve sitotoksik etkilerin konsantrasyona bağlı olarak artış gösterdiği ortaya konulmuştur.

The antiproliferative and cytotoxic effects of curcumin on human cervical cancer Hep2C cell line

Objective: In this study, antiproliferative and cytotoxic effects of different concentrations of curcumin on cervical cancer Hep2C cells were investigated with microscopic methods and MTT assay. Methods: Hep2C (human carcinoma cancer cell line, ATCC:CCL-23) cells were cultured. For cytotoxicity evaluation Hep2C cells exposed to curcumin at different concentrations of 30 μg/ml, 15 μg/ml, 7.5 μg/ml, 3.7 μg/ml, 1.9 μg/ml, 0.9 μg/ml, 0.45 μg/ml for 24 hours These Hep2C cells are evaluated with MTT assay. The IC50 value of the agent for 24 h of exposure was detected. The graph of the absorbance data obtained by the Spectramax I3 device. Viability values of Hep2C cells calculated from the absorbances obtained from MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay are gained. The preparations were observed based on changes in nuclei and structures using an inverted microscope (Leica Microsystems). Nontreated cells were used as negative control and for positive control Hep2C cells were exposed to ammonium molibdate (1mg/ml) for the above given incubation period. Results: High doses of curcumin (30 μg/ml, 15 μg/ml, 7.5 μg/ml) showed high antiproliferative and cytotoxic effects on Hep2C cells. The antiproliferative and cytotoxic effects were not observed on cervical cancer Hep2C cells treated with lower concentrations of curcumin. Conclusion: Curcumin has been shown that it is non-toxic, can be used as a highly antioxidant and antiinflammatory agent and has multifaced therapeuticpharmacological effects. However, researches on the antiproliferative, anti-cancer effects of curcumin in cervical cancer cells is not sufficient. The present study evaluates the antiproliferative and cytotoxic effects of curcumin on human cervical cancer Hep2C cells as the first time. The results of our study support these effects of curcumin on Hep2C cells in a concentrationdependent manner.

PDF

___

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1): 57-70.
2. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7(3): 683-94. 3. Gaurisankar S, Das T. Anti cancer effects of curcumin: cycle of life and death. Cell Div, 2008;3:14.
4. Das T, Gaurisankar S, Saha B, Das K. Multifocal signal modulation therapy of cancer: ancient weapon, modern targets. Mol Cell Biochem, 2010; 336(1–2): 85-95.
5. Panda AK, Chakraborty D, Sarkar I, Khan T, Gaurisankar S. New insights into therapeutic activity and anticancer properties of curcumin. J Exp Pharmacol, 2017; 9:31-45.
6. Giordano A, Tommonaro G. Curcumin and Cancer. Nutrients, 2019; 11: 2376.
7. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol, 2007; 595:1-75.
8. Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G. Death by design: where curcumin sensitizes drugresistant tumours. Anticancer Res, 2012; 32(7): 2567-84.
9. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol, 2009; 41(1): 40- 59.
10. Choudhuri T, Pal S, Das T, Sa G. Curcumin selectively induces apoptosis in deregulated cyclin D1- expressed cells at G2 phase of cell cycle in a p53- dependent manner. J Biol Chem, 2005; 280(20): 20059-68.
11. Bhattacharyya S, Mandal D, Sen GS, Suman P, Shuvomoy B, Lahiry L, et al. Tumor-induced oxidative stress perturbs nuclear factor-kappaB activity-augmenting tumor necrosis factor-alphamediated T-cell death: protection by curcumin. Cancer Res, 2007 ;67(1): 362-70.
12. Sharma RA, AJ Gescher, WP Steward. Curcumin: the story so far. Eur J Cancer, 2005; 41:1955-68.
13. Lowe SW, Cepero E, Evan G. Intrinsic tumor suppression. Nature, 2004; 432: 307-15.
14. Wilken R, Veena MS, Wang MB, Srivatsan ES. Curcumin: a review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer. 2011; 10: 12.
15. Bose S, Panda AB, Mukherjee S, Sa G. Curcumin and tumor immune editing: resurrecting the immune system. Cell Div, 2015; 10(69): 1-13.
16. Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vene R, et al. The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. Cell Physiol Biochem, 2007; 19(1-4): 137-52.
17. Wong TF, Takeda T, Li B. Curcumin disrupts uterine leiomyosarcoma cells through AKT-mTOR pathway inhibition. Gynecol Oncol, 2011; 122(1): 141-8.
18. Sun XD, Liu XE, Huang DS. Curcumin induces apoptosis of triple-negative breast cancer cells by inhibition of EGFR expression. Mol Med Rep, 2012; 6(6): 1267-70.
19. Killian PH, Kronski E, Michalik KM. Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and 2. Carcinogenesis 2012; 33(12): 2507-19.